AAlpha Bio is a biotechnology company that focuses on advancing drug discovery through its unique blend of synthetic biology and machine learning. The company’s proprietary platforms, AlphaSeq and AlphaBind, enable the measurement and prediction of protein-protein interactions at unprecedented scales, facilitating the discovery of high-impact therapeutics, including antibodies and molecular glues. Founded in 2018 as a spin-out from the University of Washington, AAlpha Bio collaborates with pharmaceutical and biotechnology companies to innovate within therapeutic areas such as oncology, infectious diseases, and neurodegeneration. The work environment is described as fast-paced and interdisciplinary, fostering a culture that values integrity, teamwork, and a commitment to improving global health. Employees can expect both collaborative and challenging projects, all while enjoying a supportive workplace in Seattle known for its access to outdoor activities.